logo-elsalys-format-site-web

July 19, 2017:  ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

ELSALYS BIOTECH, an emerging player in the field of oncology & ophthalmology, announces today that ELB021, its first-in-class monoclonal antibody targeting the cell-surface receptor CD160, has entered into a preclinical collaboration with DKFZ (the “LeukeMab Project”) under a EU-sponsored program Eurostars1.

Press release in english

Press release in french